These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 9364359)

  • 1. Combined cabergoline and recombinant human growth hormone treatment of an adolescent with a macroprolactinoma causing GH deficiency.
    Cesario F; Borretta G; Meineri I; Muratori M; Pizzocaro A; Beck-Peccoz P
    J Pediatr Endocrinol Metab; 1997; 10(2):231-6. PubMed ID: 9364359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas.
    George LD; Nicolau N; Scanlon MF; Davies JS
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):595-9. PubMed ID: 11106920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
    Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
    Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
    J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
    Sabuncu T; Arikan E; Tasan E; Hatemi H
    Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolactinoma presenting as painful postganglionic Horner syndrome.
    Talkad AV; Kattah JC; Xu MY; Orth EH; Chang JY
    Neurology; 2004 Apr; 62(8):1440-1. PubMed ID: 15111696
    [No Abstract]   [Full Text] [Related]  

  • 9. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
    Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
    Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A giant prolactinoma presenting with unilateral exophthalmos: effect of cabergoline and review of the literature.
    Berwaerts J; Verhelst J; Abs R; Appel B; Mahler C
    J Endocrinol Invest; 2000 Jun; 23(6):393-8. PubMed ID: 10908167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical therapy of macroprolactinomas in males: I. Prevalence of hypopituitarism at diagnosis. II. Proportion of cases exhibiting recovery of pituitary function.
    Sibal L; Ugwu P; Kendall-Taylor P; Ball SG; James RA; Pearce SH; Hall K; Quinton R
    Pituitary; 2002; 5(4):243-6. PubMed ID: 14558672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of macroprolactinoma with cabergoline: a study of 85 patients.
    Ferrari CI; Abs R; Bevan JS; Brabant G; Ciccarelli E; Motta T; Mucci M; Muratori M; Musatti L; Verbessem G; Scanlon MF
    Clin Endocrinol (Oxf); 1997 Apr; 46(4):409-13. PubMed ID: 9196602
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized high-dose cabergoline therapy for hyperprolactinemic infertility in women with micro- and macroprolactinomas.
    Ono M; Miki N; Amano K; Kawamata T; Seki T; Makino R; Takano K; Izumi S; Okada Y; Hori T
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2672-9. PubMed ID: 20357175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
    Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
    J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.
    Colao A; Di Sarno A; Cappabianca P; Di Somma C; Pivonello R; Lombardi G
    N Engl J Med; 2003 Nov; 349(21):2023-33. PubMed ID: 14627787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful treatment of a large macroprolactinoma with cabergoline during pregnancy.
    Liu C; Tyrrell JB
    Pituitary; 2001 Aug; 4(3):179-85. PubMed ID: 12138991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluaton of therapy with cabergoline in men with macroprolactinoa.
    Andrysiak-Mamos E; Kaźmierczyk-Puchalska A; Zochowska E; Sowińska-Przepiera E; Sagan L; Kojder I; Syrenicz A
    Pomeranian J Life Sci; 2015; 61(3):263-9. PubMed ID: 27344867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis.
    Colao A; Vitale G; Cappabianca P; Briganti F; Ciccarelli A; De Rosa M; Zarrilli S; Lombardi G
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1704-11. PubMed ID: 15070934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
    Gillam MP; Middler S; Freed DJ; Molitch ME
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.